Search results for " Radiotherapy"

showing 10 items of 156 documents

Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

2020

Objectives: Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Methods: Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. Results: The median follow-up was 84.8 months. Radiation dose did not differ significantly as a function of sex, type of SP (solitary bone plasmacytoma or as extramedullary plasmacyt…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologySolitary plasmacytomaBone NeoplasmsMultiple myeloma; Plasma cell neoplasms; Radical radiotherapy; Solitary plasmacytomaEffective dose (radiation)law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologyRadical radiotherapyTumor sizebusiness.industryGeneral MedicinePlasma cell neoplasmMiddle Agedmedicine.diseasePrognosisSurvival AnalysisRadiation therapyPlasma cell neoplasm030104 developmental biologyTreatment OutcomeOncologyItaly030220 oncology & carcinogenesisDisease ProgressionFemalePlasma cell neoplasmsNeoplasm Recurrence LocalbusinessMultiple MyelomaSolitary plasmacytomaFollow-Up StudiesPlasmacytomaJournal of cancer research and clinical oncology
researchProduct

Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI-TOF/MS.

2016

Objective: This study aims to evaluate changes in proteomic salivary profile of patients with oral mucositis after adjuvant cancer treatments. Materials and Methods: Samples were collected from patients after adjuvant cancer therapies, and were analyzed by means of SELDI/TOF. Patients were separated in two groups: patients affected by mucositis (MUCOSITIS) and patient without mucositis (NO MUCOSITIS). All patients were divided in function of the anticancer treatment: patients who had radiotherapy (MUCOSITIS RADIO), had not radiotherapy (MUCOSITIS NO RADIO), had chemotherapy (MUCOSITIS CHEMO), and those who had not chemotherapy (MUCOSITIS NO CHEMO). Statistical evaluation PCA (Principal Comp…

0301 basic medicineAdultMalemedicine.medical_specialtySalivaPathologymedicine.medical_treatmentGastroenterologySELDI-TOF/MS; biomarker discovery; oral mucositis; saliva; Adult; Aged; Aged 80 and over; Biomarkers; Chemotherapy Adjuvant; Female; Humans; Male; Middle Aged; Neoplasms; Radiation Injuries; Radiotherapy Adjuvant; Saliva; Stomatitis; Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsbiomarker discoverymedicineMucositisHumansRadiation InjurieRadiation InjuriesSalivaGeneral DentistryStomatitisAgedAged 80 and overChemotherapyStomatitisbusiness.industryCancerSELDI-TOF/MSBiomarkerMiddle Agedmedicine.diseaseStomatitiRadiation therapy030104 developmental biologyOtorhinolaryngologyChemotherapy Adjuvant030220 oncology & carcinogenesisSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBiomarker (medicine)NeoplasmFemaleRadiotherapy AdjuvantbusinessAdjuvantoral mucositiBiomarkersHumanOral diseases
researchProduct

Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Compariso…

2021

The objective of this study is to conduct a qualitative and a quantitative image quality and lesion evaluation in patients undergoing MR-guided radiation therapy (MRgRT) for prostate cancer on a hybrid magnetic resonance imaging and linear accelerator system (MR-Linac or MRL) at 1.5 Tesla. This prospective study was approved by the institutional review board. A total of 13 consecutive patients with biopsy-confirmed prostate cancer and an indication for MRgRT were included. Prior to radiation therapy, each patient underwent an MR-examination on an MRL and on a standard MRI scanner at 3 Tesla (MRI3T). Three readers (two radiologists and a radiation oncologist) conducted an independent qualita…

0301 basic medicineCancer ResearchIntraclass correlationImage qualityPIRADSFleiss' kappalcsh:RC254-282ArticleLesion03 medical and health sciences0302 clinical medicineimage qualityMedicineEffective diffusion coefficientimage guidanceRadiation oncologistMR-Linacmedicine.diagnostic_testbusiness.industryMagnetic resonance imaginglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslesion detection030104 developmental biologyadaptive radiotherapyOncologyprostate carcinoma030220 oncology & carcinogenesismpMRImedicine.symptombusinessNuclear medicineKappaCancers
researchProduct

Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Tr…

2019

Background: Isometric paravertebral muscle training (IPMT) may improve mobility, pain, and quality of life (QOL) in cancer patients with spinal metastases. However, this regimen remains unproven in patients with unstable spinal metastases (USM), a population at high risk for clinical exacerbation with such interventions. Thus, we conducted this exploratory, non-blinded, randomized controlled trial (NCT02847754) to evaluate the safety/feasibility of IPMT and secondarily assess pain, bone density, pathologic fracture rate, and QOL. Methods: All patients had histologically/radiologically confirmed USM (per Taneichi score) and underwent non-operative management with 5&ndash

0301 basic medicineCancer Researchmedicine.medical_specialtyPathologic fractureVisual analogue scalePopulationunstablelcsh:RC254-282Articlelaw.inventionspine metastases03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawInternal medicineClinical endpointMedicineeducationeducation.field_of_studytrainingbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRegimen030104 developmental biologyMuscle relaxationOncology030220 oncology & carcinogenesispalliative radiotherapybusinessCancers
researchProduct

Adjuvant Radiotherapy After Minimally Invasive Surgery in Patients With Stage IA1-IIA1 Cervical Cancer

2021

To estimate whether adjuvant radiotherapy is necessary for patients with stage IA1-IIA1 cervical cancer after laparoscopic hysterectomy, 221 patients were retrospectively analyzed. Sixty-two of them were treated with laparoscopic hysterectomy and adjuvant radiotherapy (group A), 115 underwent open surgery (group B) and 44 received laparoscopic hysterectomy alone (group C). Results showed that the 3-year local recurrence-free survival (LRFS) rates of group A, B and C were 98.4%, 97.4% and 86.4%, respectively. The LRFS rates of group A and B surpassed C (A vs. B, p=0.634; A vs. C, p=0.011; B vs. C, p=0.006). The inter-group differences of 3-year overall survival (OS) and distant metastasis fr…

0301 basic medicineCancer Researchmedicine.medical_specialtycervical cancerUrologySubgroup analysissurvivalGroup AGroup Bopen surgery03 medical and health sciences0302 clinical medicinemedicineStage (cooking)minimally invasive surgeryRC254-282Original ResearchCervical cancerAdjuvant radiotherapybusiness.industryOpen surgeryLaparoscopic hysterectomyNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesislaparoscopic hysterectomybusinessadjuvant radiotherapyFrontiers in Oncology
researchProduct

Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation

2019

Background and purpose: To analyze deviations of the applied from the planned doses on a voxel-by-voxel basis for definitive prostate cancer radiotherapy depending on anatomic variations and imaging frequency. Materials and methods: Daily in-room CT imaging was performed in treatment position for 10 patients with prostate cancer undergoing intensity-modulated radiotherapy (340 fraction CTs). Applied fraction doses were recalculated on daily images, and voxel-wise dose accumulation was performed using a deformable registration algorithm. For weekly imaging, weekly position correction vectors were derived and used to rigidly register daily scans of that week to the planning CT scan prior to d…

0301 basic medicineCancer Researchmedicine.medical_treatmentRectumlcsh:RC254-28203 medical and health sciencesProstate cancerorgans-at-risk0302 clinical medicineProstateDosimetryMedicineOriginal ResearchDose accumulationdosimetrybusiness.industryimage-guided radiotherapymedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstumor control probabilityRadiation therapyConformity index030104 developmental biologymedicine.anatomical_structureOncologyTreatment delivery030220 oncology & carcinogenesisbusinessNuclear medicineFrontiers in Oncology
researchProduct

Stratégies en cas de positivité du ganglion sentinelle dans les cancers du sein

2020

Resume Les strategies de prise en charge en cas de ganglion(s) sentinelle(s) micro ou macrometastatique(s) dans les cancers du sein ont ete profondement modifiees depuis une dizaine d’annees et la publication de cinq essais randomises : ACOSOG Z0011, IBCSG 23-01, et AATRM comparant curage axillaire versus abstention ; et AMAROS et OTOASOR comparant curage axillaire versus radiotherapie axillaire. Malgre les limites methodologiques de certains de ces essais, notamment de l’ACOSOG Z0011, les recommandations internationales (ASCO, NCCN) et le consensus d’experts de St Gallen ne preconisent pas la realisation d’un curage axillaire complementaire en cas d’envahissement macro ou micrometastatique…

0301 basic medicineGynecologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicine03 medical and health sciences030104 developmental biology0302 clinical medicineAxillary radiotherapyOncology030220 oncology & carcinogenesismedicineRadiology Nuclear Medicine and imagingbusinessBulletin du Cancer
researchProduct

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review

2020

Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment of painful bone metastases, however only a limited number of metastases can be irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC through a systematic review. Methods: Systematic review including all prospective articles published between 01-1994 and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: nonradiation based trials evaluating CIBP early pain relief options (initially defined as pain score evaluated within two weeks, because of no randomized trials, …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPain reliefcancer induced bone painCochrane Librarylcsh:RC254-282DISEASEpain relieflaw.inventionPALLIATIVE RADIOTHERAPY03 medical and health sciences0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beingbone metastasessystematic reviewlawQUALITY-OF-LIFEInternal medicinemedicineLung cancerBone painIBANDRONATEbisphosphonatesnon-small cell lung cancerDENOSUMABbusiness.industryGold standardCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensEFFICACYRadiation therapy1ST-LINE TREATMENT030104 developmental biologyMETASTASESOncology030220 oncology & carcinogenesisZOLEDRONIC ACIDmedicine.symptombusinessFrontiers in Oncology
researchProduct

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

2021

Breast cancer (BC) heterogeneity is composite in nature, with a wide variety of factors concurring to define several pathological entities, which differ by clinical presentation, pathologic features, therapy administered, and inherent outcomes1. Additional sources of breast cancer heterogeneity may raise during the disease course. In BC patients whose disease was initially diagnosed in the early stage and subsequently progressed with metastatic involvement of one single or multiple site/s, the molecular characteristics of metastatic lesions do not necessary mimic those of the disease initially diagnosed. A well-depicted molecular landscape is crucial for subtype definition, prognostic evalu…

0301 basic medicineOncologyCancer therapyReceptor ErbB-2medicine.medical_treatmentAdo-Trastuzumab Emtansineprogesterone receptorSettore MED/060302 clinical medicinehuman epidermal growth factor receptor 2 (HER2)Antineoplastic Combined Chemotherapy ProtocolsestrogenNeoplasm Metastasisskin and connective tissue diseasesMultidisciplinaryBrain NeoplasmsQRMiddle AgedPrognosisMetastatic breast cancerNeoplasm Metastasi030220 oncology & carcinogenesisMedicineFemalePertuzumabmetastatic breast cancerReceptors ProgesteroneBreast NeoplasmHER2 positivitymedicine.drugHumanAdultmedicine.medical_specialtymedicine.drug_classSciencetrastuzumab-emtansineBreast Neoplasmsmetastatic breast cancer; HER2 positivity; cancerArticleDisease-Free SurvivalBrain Neoplasm03 medical and health sciencesBreast cancerbreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicineProgesterone receptormedicineHumanscancerbreast cancer; human epidermal growth factor receptor 2 (HER2); pertuzumab; trastuzumab-emtansine; estrogen; progesterone receptorneoplasmsAgedChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancermedicine.diseaseHER2-positiveBreast cancer; oncology; radiotherapy; chemotherapy; HER2Radiation therapy030104 developmental biologyEstrogenbusinessprognostic relevance
researchProduct

Involvement of non-coding RNAs in chemo- and radioresistance of colorectal cancer

2016

Despite recent progress in understanding the cancer signaling pathways and in developing new therapeutic strategies, however, the resistance of colorectal cancer (CRC) cells to chemo- and radiotherapy represents the main hurdle to the successful treatment, leading to tumor recurrence and, consequently, a poor prognosis. Therefore, overcoming drug and radiation resistance, enhancing drug and radiation sensitivity of CRC cells, and improving the effi cacy of chemo- and radiotherapy have an important signifi cance in the treatment of CRC. The identifi cation of new molecular biomarkers which can predict therapy response and prognosis is one of the most signifi cant aims in pharmacogenomics and…

0301 basic medicineOncologyDrugmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentmedia_common.quotation_subjectTherapy responseBiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineRadioresistanceInternal medicinemicroRNAmedicineChemotherapyNon-coding RNAneoplasmsChemoresistance; Chemotherapy; miRNAs; Non-coding RNA; Predictive biomarkers; Radioresistance; Radiotherapy; Targeted therapy; Therapy response; Medicine (all); Biochemistry Genetics and Molecular Biology (all)miRNAmedia_commonChemotherapyBiochemistry Genetics and Molecular Biology (all)RadiotherapyMedicine (all)Radioresistancemedicine.diseaseRadiation therapyPredictive biomarker030104 developmental biology030220 oncology & carcinogenesisPharmacogenomicsChemoresistance
researchProduct